Back to news

Novartis Slides as Investors Appear to Lock In Gains Ahead of Q3 Results

Investivoq PriceTracker

Novartis AG (NVS) is down 4.1% today. Here is some analysis on what might have caused this price movement.

Analysis: A single clear negative catalyst is hard to confirm. This could be because investors are taking profits and reducing exposure ahead of Novartis’ third-quarter results on October 27, 2026, especially after the stock recently reached a one-month high and had rebounded from September’s pipeline-related setbacks.

Details:

  • Novartis’ investor calendar shows third-quarter 2026 results are scheduled for October 27, 2026, which can prompt cautious trading before the report.
  • The shares had recently pushed to a one-month high, and market data shows the stock was up roughly 9.6% over the past month before today’s pullback.
  • Recent company updates have been broadly constructive, including a European approval for Cosentyx in polymyalgia rheumatica on October 21 and new Kisqali survival data released on October 23, so today’s decline does not appear tied to an obvious fresh operational setback.
  • That leaves positioning and sentiment as the most likely explanation, with some investors still sensitive to the late-stage trial disappointments Novartis disclosed in early September.

    • Sources:

    Novartis, MarketBeat, SEC, GlobeNewswire

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    Investivoq Alerts
    Receive NVS Data Alerts
    Get market-moving data, filings, and signals for NVS in real time.
    Sign Up

    $NVS Hedge Fund Activity

    We have seen 616 institutional investors add shares of $NVS stock to their portfolio, and 708 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DODGE & COX removed 6,208,010 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $972,919,327
    • GOLDMAN SACHS GROUP INC removed 3,545,603 shares (-54.3%) from their portfolio in Q2 2026, for an estimated $555,666,902
    • JPMORGAN CHASE & CO added 2,264,447 shares (+inf%) to their portfolio in Q2 2026, for an estimated $354,884,133
    • FISHER ASSET MANAGEMENT, LLC added 1,637,629 shares (+11.8%) to their portfolio in Q2 2026, for an estimated $256,649,216
    • HOLOCENE ADVISORS, LP added 1,037,332 shares (+inf%) to their portfolio in Q2 2026, for an estimated $162,570,671
    • PRIMECAP MANAGEMENT CO/CA/ removed 975,230 shares (-12.9%) from their portfolio in Q2 2026, for an estimated $152,838,045
    • MILLENNIUM MANAGEMENT LLC added 758,029 shares (+inf%) to their portfolio in Q2 2026, for an estimated $118,798,304

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $NVS Congressional Stock Trading

    Members of Congress have traded $NVS stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $NVS stock by members of Congress over the last 6 months:

    • REPRESENTATIVE KEVIN HERN sold up to $50,000 on 08/27.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.